Ribociclib/Ribociclib is an anti-cancer drug developed in which country?

Ribociclib is an oral anti-cancer targeted drug developed by the Swiss pharmaceutical company Novartis. It is a selective CDK4/6 inhibitor. The drug was developed to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Although this type of breast cancer depends on hormone signals for growth, it is also prone to resistance to endocrine therapy. CDK4/6 is a type of protein kinase closely related to the cell cycle, which can promote the transition of cells from the G1 phase to the S phase, thus promoting the proliferation of tumor cells. Riboxiclib is a cell cycle-specific inhibitor by selectively inhibiting CDK4/6 activity and arresting the cell cycle, thereby preventing cancer cell proliferation.

Ribociclib was initially approved by the U.S. FDA in 2017 under the trade name Kisqali, making it the second CDK4/6 inhibitor after Palbociclib. Its listing is based on the positive results of the MONALEESA series of clinical trials, which showed that combination with aromatase inhibitors or fulvestrant can significantly extend progression-free survival and overall survival. One of the clinical advantages of ribociclib lies in its long-term improvement in survival of women with advanced breast cancer, especially in premenopausal and postmenopausal women. It has shown good efficacy and safety.

At present, Riboxiclib has been approved by many countries and regions for the first-line or second-line treatment of HR+/HER2- locally advanced or metastatic breast cancer, and is included in the medical insurance catalog in many countries in Europe, America and Asia. In China, Riboxiclib has also been approved and marketed for use in combination with aromatase inhibitors as the initial treatment for postmenopausal women with HR+/HER2- advanced breast cancer, further enriching the targeted treatment options for Chinese breast cancer patients.

Reference materials:https://us.kisqali.com/